ATE233097T1 - Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung - Google Patents

Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung

Info

Publication number
ATE233097T1
ATE233097T1 AT98957624T AT98957624T ATE233097T1 AT E233097 T1 ATE233097 T1 AT E233097T1 AT 98957624 T AT98957624 T AT 98957624T AT 98957624 T AT98957624 T AT 98957624T AT E233097 T1 ATE233097 T1 AT E233097T1
Authority
AT
Austria
Prior art keywords
formulations
sustained release
igf
producing sustained
release igf
Prior art date
Application number
AT98957624T
Other languages
English (en)
Inventor
Bret Shirley
Maninder Hora
Derek O'hagan
Manmohan Singh
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE233097T1 publication Critical patent/ATE233097T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98957624T 1997-11-07 1998-11-06 Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung ATE233097T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6489197P 1997-11-07 1997-11-07
US9606698P 1998-08-11 1998-08-11
PCT/US1998/023627 WO1999024061A1 (en) 1997-11-07 1998-11-06 Method for producing igf-1 sustained-release formulations

Publications (1)

Publication Number Publication Date
ATE233097T1 true ATE233097T1 (de) 2003-03-15

Family

ID=26745003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957624T ATE233097T1 (de) 1997-11-07 1998-11-06 Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung

Country Status (7)

Country Link
US (1) US6573238B2 (de)
EP (1) EP1028746B1 (de)
JP (1) JP2001522812A (de)
AT (1) ATE233097T1 (de)
AU (1) AU1384199A (de)
DE (1) DE69811710T2 (de)
WO (1) WO1999024061A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
US6303138B1 (en) 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
WO2001058426A1 (en) * 2000-02-09 2001-08-16 White Spot Ag Sustained release composition comprising insuline like growth factor
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7252842B2 (en) † 2000-12-21 2007-08-07 Alrise Biosystems Gmbh Induced phase transition method for the production of microparticles containing hydrophilic active agents
EP1450766B1 (de) * 2001-10-10 2015-04-22 Pierre Fabre Medicament Biologisch abbaubare mikrokügelchen mit verlängerter freisetzung und verfahren zu ihrer herstellung
NZ535008A (en) * 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1629833A4 (de) * 2003-06-03 2010-04-21 Santen Pharmaceutical Co Ltd Verfahren zur herstellung eines mikroteilchens
US20050175709A1 (en) 2003-12-11 2005-08-11 Baty Ace M.Iii Therapeutic microparticles
WO2006026730A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Cultured three dimensional tissues and uses thereof
HUE031550T2 (en) * 2007-06-06 2017-07-28 Debiopharm Res & Mfg Sa Slow release pharmaceutical composition made of microparticles
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
US7910123B2 (en) 2007-09-05 2011-03-22 Warsaw Orthopedic Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
EP2207568B1 (de) 2007-11-16 2017-05-31 The Rockefeller University Für die protofibrillenform des proteins beta-amyloid spezifische antikörper
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
JP2013523752A (ja) * 2010-03-29 2013-06-17 エボニック デグサ コーポレイション 局所投与部位における医薬組成物の保持改善のための組成物および方法
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
US10519434B2 (en) 2012-07-13 2019-12-31 Diomics Corporation Biologic sample collection devices and methods of production and use thereof
EP3179912B1 (de) * 2014-08-15 2020-10-14 Diomics Corporation Filme zur entnahme und analyse biologischer analyten sowie verfahren zur herstellung
EP3414573B1 (de) 2016-02-10 2023-11-08 Rutgers, the State University of New Jersey Neue anti-lam antikörper
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
KR102034872B1 (ko) * 2018-01-10 2019-10-21 주식회사 지투지바이오 콜라겐 펩타이드가 함유된 폴리카프로락톤 미립구 필러 및 그 제조방법
US20220218814A1 (en) * 2019-05-10 2022-07-14 Academia Sinica A vaccine comprising a nanoparticle encapsulating epitopes and adjuvant for neutralizing virus infection
WO2021167957A1 (en) * 2020-02-20 2021-08-26 Dianomi Therapeutics, Inc. Inorganic coatings for the sustained release of bioactive compounds
EP4281044A1 (de) * 2021-01-22 2023-11-29 University of Connecticut Synthetische künstliche stammzellen (sasc)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH679207A5 (de) 1989-07-28 1992-01-15 Debiopharm Sa
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
DE69415684T2 (de) 1993-10-22 1999-06-10 Genentech Inc., San Francisco, Calif. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
AU1384799A (en) 1997-11-07 1999-05-31 Chiron Corporation Novel igf-i composition and its use

Also Published As

Publication number Publication date
US6573238B2 (en) 2003-06-03
US20020013273A1 (en) 2002-01-31
EP1028746A1 (de) 2000-08-23
JP2001522812A (ja) 2001-11-20
DE69811710T2 (de) 2004-03-25
EP1028746B1 (de) 2003-02-26
DE69811710D1 (de) 2003-04-10
WO1999024061A1 (en) 1999-05-20
AU1384199A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
DE69811710D1 (de) Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
ATE268591T1 (de) Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
DE69806988D1 (de) Verfahren zur Herstellung von Mitteln mit gesteuerter Freisetzung
ATE234124T1 (de) Verfahren zur herstellung von wirkstoffhaltigen knochenzementen
ATE324885T1 (de) Verfahren zur herstellung von fenofibrathaltigen arzneizusammensetzungen mit erhöhter bioverfügbarkeit
DE69822960D1 (de) Verfahren zur Herstellung von L-Leucin
ATE319422T1 (de) Verfahren zur herstellung von pulverformulierungen
DE68904291D1 (de) Verfahren zur herstellung von geliermittel-suesswaren.
DE69621491D1 (de) Verfahren zur Herstellung von Epsilon-Caprolactam
DE60011525D1 (de) Verfahren zur herstellung von cycloalkanonen
DE69331460D1 (de) Ein verbessertes verfahren zur herstellung von wachsfreien kaugummis mit kurzen härtungszeiten
DE69715070D1 (de) Verfahren zur Herstellung von Quantum-Teilungsphosphoren
DE69803882D1 (de) Verfahren zur herstellung von karbonierten hydroxyapatitzusammensetzungen
ATE262576T1 (de) Verfahren zur herstellung von weichmittelzusammensetzungen
DE3878382D1 (de) Verfahren zur herstellung von isomerisierten hopfenpellets.
DE69712779D1 (de) Verfahren zur herstellung von kunststeinen
DE59310184D1 (de) Verfahren zur herstellung dünnflüssiger, lagerstabiler amphotenside
DE59705690D1 (de) Verfahren zur herstellung von aliphatischen alpha, omega-aminonitrilen
DE59306461D1 (de) Verfahren zur herstellung von lagerstabilen nichtionischen tensiden
DE69709625D1 (de) Verfahren zur herstellung von epsilon-caprolactam von 6-aminocaprosäure
DE59803057D1 (de) Verfahren zur Herstellung von Cyclohexanonen
DE69823275T2 (de) Verfahren zur Herstellung von Vorrichtungen zur kontrollierten Freisetzung von Arzneimitteln
ATE296850T1 (de) Verfahren zur herstellung von polyamiden
DE59803655D1 (de) Verfahren zur herstellung von aliphatischen alpha, omega-aminonitrilen
ATE300517T1 (de) Verbindungen und verfahren zur herstellung substituierter 4-phenyl-4-cyanocyclohexansäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties